aTyr Pharma (LIFE) Tops Q3 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
November 10, 2021 4:00 PM ESTPositive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target.
Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022.
September follow-on common stock offering generated $80 million in net proceeds.
Company to host conference call and webcast today, November 10th, at 5:00 p.m. EST / 2:00 p.m. PST.
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:... More
